Unregistered User If this is not your name, click here.
		Contact Us | Order Now | Journals | Bookstore | Register a colleague
	Select a ChannelAcneAIDS and HIVAllergy OtherAlzheimer'sAnaesthesiology OtherAngina Pectoris/MIAnxietyArthritis OtherAsthmaBack PainBacterial InfectionsBladder CancerBone Marrow TransplantationBreast CancerCardiology OtherCataractCell TransplantationCervical CancerCholesterol/Lipid disordersCirrhosisClinical PharmacologyColorectal CancerCongestive Heart FailureContact DermatitisContraceptionCOPDCystic FibrosisDental and Oral DisordersDepressionDermatology OtherDiabetesDialysisEating DisordersElbowEmergency MedicineEndocrinology OtherEpilepsyErectile DysfunctionFibromyalgiaGastro OtherGeneticsGenitourinary OtherGeriatricsGERD/GastritisGlaucomaH. Pylori/UlcerHaematology OtherHair LossHeadachesHepa/Biliary OtherHepatitisHipHRTHypertensionIBDImmunologyInfectious OtherInfertilityIntensive CareIrritable Bowel SyndromeKneeLeukemiasLiver CancerLung CancerLupusLymphomasMelanomaMenopauseMultiple Sclerosis Nephrology OtherNeurologic OtherNutritional / Metabolic OtherOb/Gyn OtherObesityOncology OtherOphth. OtherOphthalmic SurgeryOrgan TransplantationOrthopaedics OtherOsteoarthritisOsteoporosisOtitisOtorhino. OtherOvarian CancerPaediatricsPainPancreatic CancerParkinson'sPregnancyProstate CancerPsychiatry OtherPulmonary OtherRadiologyRenal CancerRenal FailureRespiratory InfectionsRheumatoid arthritisRheumatology OtherRhinitisSchizophreniaShoulderSleep ApnoeaSleep DisordersSpineStrokeSTDsSurgeryThyroid DisordersTransfusionTransplant Surgery OtherTraumaUrinary IncontinenceUrinary tract infectionsVaccinologyVascular DisordersViral Infections

SEARCH   News Bookstore Medline The Web Meetings & Congresses Complete Doctor's Guide    EXPLORE :    All News   All Webcasts   All Cases   All Meetings & Congresses   All Medical Resources New drugs / indications English Dictionary Medical Dictionary Thesaurus Warning | Privacy | Awards  Favourite Journals  Click here to choose your favourite journals  Favourite Sites  Click here to choose your favourite sites  Languages  Select languageEnglishFrançais

Use of Statins Does Not Interfere With Efficacy of Maraviroc: Presented at IAS By Charlene Laino CAPE TOWN, South Africa -- July 21, 2009 -- The antiviral efficacy of maraviroc does not appear to be influenced by coadministration of statins in patients with HIV, according to an analysis of data from the Maraviroc Versus Optimized Therapy in Viremic Antiretroviral Treatment-Experienced Patients (MOTIVATE) studies. Graeme Moyle, MD, HIV Research Strategy, Chelsea and Westminster Hospital, London, United Kingdom, presented the results here on July 20 at the 5th International AIDS Society (IAS) Conference on HIV Pathogenesis, Treatment and Prevention. Maraviroc, a CC chemokine receptor 5 (CCR5) antagonist, prevents cellular entry of CCR5-tropic strains of HIV by binding to cell-surface CCR5 and blocking its interaction with envelope gp120. CCR5 receptors are located on cholesterol-rich lipid rafts within cell membranes. Statins, which are 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors (HMG CoA reductase inhibitors), may reduce lipid raft numbers, thus potentially altering CCR5 availability, Dr. Moyle explained. For the study, the researchers performed a post hoc analysis of pooled data from the MOTIVATE 1 and 2 studies, which demonstrated superior efficacy for maraviroc over placebo in triple-class resistant and/or experienced patients. Patients were considered to be on statins if statins were initiated prior to or at baseline and continued throughout the study or stopped at least 300 days post baseline. Overall, 84 of 840 patients on maraviroc and 19 of 209 patients on placebo in the 2 trials were on a statin. At baseline, both the no-statin and the statin groups had similar HIV-1 RNA concentrations across the 2 treatment arms: 4.9 versus 4.9 log10 copies/mL for maraviroc and placebo patients in the no-statin arm and 4.6 versus 4.5 log10 copies/mL for maraviroc and placebo patients in the statin arm. The mean reduction in HIV-1 RNA at week 48 was comparable between the 2 statin groups: -1.7 versus -0.8 log10 copies/mL for maraviroc versus placebo patients in the no-statin arm and -1.9 versus -0.6 log10 copies/mL for maraviroc versus placebo patients in the statin arm. The proportion of patients with HIV-1 RNA <50 copies/mL at week 48 were 47% versus 20% for maraviroc versus placebo patients in the no-statin arm, and 57% versus 11% for maraviroc versus placebo patients in the statin arm, respectively. "There was no significant difference in the odds ratios between the maraviroc and placebo arms of achieving <50 copies/mL across the 2 statin groups (P = .167)," said Dr. Moyle. "The median changes in CD4+ cell counts were also broadly comparable between the 2 groups." Funding for this study was provided by Pfizer Inc. [Presentation title: Concurrent Use of Statins Does Not Influence Efficacy of Maraviroc in MOTIVATE Studies. Abstract MOPEB039] E-mail this page to a friend or colleague! To print, use this version